DIN 02519291 — SKYRIZI 150 MG
SKYRIZI is a solution of Risankizumab marketed by ABBVIE CORPORATION. The full Risankizumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02519291
- Brand name
- SKYRIZI
- Active ingredient
- Risankizumab
- Strength
- 150 MG
- Dosage form
- SOLUTION
- Route
- SUBCUTANEOUS
- Manufacturer
- ABBVIE CORPORATION
- Health Canada status
- MARKETED
- Drug class
- Interleukin-23 (IL-23) inhibitor (monoclonal antibody)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Risankizumab products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02519283 | SKYRIZI | 150 MG | SOLUTION | ABBVIE CORPORATION | MARKETED |
| 02552507 | SKYRIZI | 180 MG | SOLUTION | ABBVIE CORPORATION | MARKETED |
| 02532093 | SKYRIZI | 360 MG | SOLUTION | ABBVIE CORPORATION | MARKETED |
| 02532107 | SKYRIZI | 60 MG | SOLUTION | ABBVIE CORPORATION | MARKETED |